Active substance: Gabapentin
+ free Neurontin pill.
While initially believed to act on the GABAergic neurotransmitter system, its actual mechanism of action as an anticonvulsant and therapeutically for neuropathy, is unknown.
As the GABA system is the most prolific class of inhibitory receptors within the brain, its modulation results in the sedating or calming effects of GBP on the nervous system.
GBP does not appear to bind to any proteins, nor does it induce or inhibit hepatic microsomal enzymes. Instead, it is eliminated unchanged by renal excretion.
GBP offers a favorable safety profile with minimal reported drug—drug interactions. It is not associated with hematologic or hepatic problems and does not require serum concentration monitoring.
In addition to these pharmacological advantages, animal experiment data support the use of GBP for the treatment of psychiatric disorders. Previously published systematic reviews, case series, case reports, opinions, comments, and unpublished studies were excluded from this review.
The search was carried out by two independent volunteer researchers PK and MA. These researchers independently performed screening of titles and abstracts for initial exclusion based on publication type.
Where required, the full texts were immediately screened to ascertain inclusion or exclusion. Following the initial exclusion screening, the researchers further evaluated the full-text articles for inclusion based on the four inclusion criteria.
At each step, their results were compared, and any discrepancies were resolved through discussion.
Any remaining disagreements were resolved by involving a third independent researcher SA. After excluding all duplicates and completely off-topic titles,088 citations were left.
Remaining citations were manually screened for exclusion based on their titles and abstracts. A manual search of references revealed 190 additional articles. Subsequently, full-text articles were obtained for those 191 references that appeared to match our inclusion criteria.
Out of those, 137 papers did not fit the inclusion criteria. A final total of 54 articles were found for the purpose of the study Figure 1. Il massimo intervallo tra le dosi nello schema di somministrazione tre volte al giorno non deve superare le 12 ore.